MCRB – Seres Therapeutics, Inc.
Seres Therapeutics, Inc.MCRB
$0.37Name : Seres Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $64,512,832.00
EPSttm : -0.81
Seres Therapeutics, Inc.
$0.37
7.48%$0.0299Float Short %
12.56
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
EPS Last/This Y
-0.06
EPS This/Next Y
-0.2
Price
0.37
Target Price
4.08
Analyst Recom
2.2
Performance Q
-49.66
Relative Volume
2.24
Beta
2.99
Ticker: MCRB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | MCRB | 0.707 | 0.05 | 0.00 | 24347 |
| 2025-03-24 | MCRB | 0.7199 | 0.05 | 0.24 | 11569 |
| 2025-03-25 | MCRB | 0.71 | 0.05 | 0.00 | 11801 |
| 2025-03-26 | MCRB | 0.7212 | 0.05 | 0.00 | 11826 |
| 2025-03-27 | MCRB | 0.7588 | 0.06 | 0.00 | 11729 |
| 2025-03-28 | MCRB | 0.7385 | 0.06 | 0.01 | 11862 |
| 2025-03-31 | MCRB | 0.7003 | 0.06 | 0.42 | 11797 |
| 2025-04-01 | MCRB | 0.6742 | 0.06 | 999.99 | 11773 |
| 2025-04-02 | MCRB | 0.6816 | 0.06 | 0.50 | 11771 |
| 2025-04-03 | MCRB | 0.6925 | 0.06 | 1.33 | 11770 |
| 2025-04-04 | MCRB | 0.64 | 0.06 | 0.00 | 11773 |
| 2025-04-07 | MCRB | 0.5723 | 0.06 | 0.21 | 11837 |
| 2025-04-08 | MCRB | 0.52 | 0.06 | 0.00 | 11856 |
| 2025-04-09 | MCRB | 0.5398 | 0.06 | 0.08 | 11855 |
| 2025-04-10 | MCRB | 0.5874 | 0.06 | 0.00 | 11912 |
| 2025-04-11 | MCRB | 0.5903 | 0.05 | 0.04 | 12177 |
| 2025-04-14 | MCRB | 0.6633 | 0.05 | 0.00 | 12280 |
| 2025-04-15 | MCRB | 0.464 | 0.05 | 0.03 | 12334 |
| 2025-04-16 | MCRB | 0.397 | 0.05 | 0.00 | 12316 |
| 2025-04-17 | MCRB | 0.37 | 0.05 | 0.77 | 12217 |
| 2025-04-18 | MCRB | 0.37 | 0.05 | 0.66 | 12217 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | MCRB | 0.71 | 129.6 | - | -0.06 |
| 2025-03-24 | MCRB | 0.71 | 129.6 | - | -0.06 |
| 2025-03-25 | MCRB | 0.71 | 129.6 | - | -0.06 |
| 2025-03-26 | MCRB | 0.73 | 129.6 | - | -0.06 |
| 2025-03-27 | MCRB | 0.76 | 129.6 | - | -0.06 |
| 2025-03-28 | MCRB | 0.72 | 129.6 | - | -0.06 |
| 2025-03-31 | MCRB | 0.70 | 129.6 | - | -0.06 |
| 2025-04-01 | MCRB | 0.68 | 129.6 | - | -0.06 |
| 2025-04-02 | MCRB | 0.68 | 129.6 | - | -0.06 |
| 2025-04-03 | MCRB | 0.69 | 129.6 | - | -0.06 |
| 2025-04-04 | MCRB | 0.65 | 129.6 | - | -0.06 |
| 2025-04-07 | MCRB | 0.57 | 129.6 | - | -0.06 |
| 2025-04-08 | MCRB | 0.52 | 129.6 | - | -0.06 |
| 2025-04-09 | MCRB | 0.54 | 129.6 | - | -0.06 |
| 2025-04-10 | MCRB | 0.59 | 129.6 | - | -0.06 |
| 2025-04-11 | MCRB | 0.59 | 129.6 | - | -0.06 |
| 2025-04-14 | MCRB | 0.66 | 129.6 | - | -0.06 |
| 2025-04-15 | MCRB | 0.46 | 129.6 | - | -0.06 |
| 2025-04-16 | MCRB | 0.40 | 129.6 | - | -0.06 |
| 2025-04-17 | MCRB | 0.37 | 129.6 | - | -0.06 |
| 2025-04-18 | MCRB | 0.37 | 129.6 | - | -0.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | MCRB | -0.13 | -0.78 | 13.52 |
| 2025-03-24 | MCRB | -0.13 | -0.79 | 13.52 |
| 2025-03-25 | MCRB | -0.13 | -0.79 | 13.52 |
| 2025-03-26 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-03-27 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-03-28 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-03-31 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-01 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-02 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-03 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-04 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-07 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-08 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-09 | MCRB | -0.13 | -0.79 | 13.12 |
| 2025-04-10 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-11 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-14 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-15 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-16 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-17 | MCRB | -0.13 | -0.79 | 12.56 |
| 2025-04-18 | MCRB | -0.13 | -0.79 | 12.56 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.08
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
-0.13
Institutional Transactions
-0.79
Beta
2.99
Average Sales Estimate Current Quarter
20
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
18
Sentiment Score
10
Actual DrawDown %
99
Max Drawdown 5-Year %
-99
Target Price
4.08
P/E
Forward P/E
PEG
P/S
P/B
4.64
P/Free Cash Flow
EPS
-0.96
Average EPS Est. Cur. Y
-0.06
EPS Next Y. (Est.)
-0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
2.24
Return on Equity vs Sector %
-19
Return on Equity vs Industry %
-5.6
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.35
EBIT Estimation
Seres Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 103
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today
news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance
stock history MCRB – Seres Therapeutics, Inc. invest stock market
stock prices MCRB premarket after hours
ticker MCRB fair value insiders trading